The effect of timing of oseltamivir chemoprophylaxis in controlling influenza A H3N2 outbreaks in long-term care facilities in Manitoba, Canada, 2014-2015: a retrospective cohort study.
Identifieur interne : 000037 ( Main/Exploration ); précédent : 000036; suivant : 000038The effect of timing of oseltamivir chemoprophylaxis in controlling influenza A H3N2 outbreaks in long-term care facilities in Manitoba, Canada, 2014-2015: a retrospective cohort study.
Auteurs : Davinder Singh [Canada] ; Depeng Jiang [Canada] ; Paul Van Caeseele [Canada] ; Carla Loeppky [Canada]Source :
- Infection control and hospital epidemiology [ 1559-6834 ] ; 2018.
Descripteurs français
- KwdFr :
- Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Chimioprévention (), Facteurs temps, Flambées de maladies (), Grippe humaine (), Grippe humaine (traitement médicamenteux), Grippe humaine (épidémiologie), Humains, Infection croisée (), Infection croisée (microbiologie), Infection croisée (traitement médicamenteux), Infection croisée (épidémiologie), Manitoba (épidémiologie), Modèles logistiques, Oséltamivir (administration et posologie), Oséltamivir (usage thérapeutique), Soins de longue durée, Sous-type H3N2 du virus de la grippe A, Études rétrospectives.
- MESH :
- administration et posologie : Antiviraux, Oséltamivir.
- microbiologie : Infection croisée.
- traitement médicamenteux : Grippe humaine, Infection croisée.
- usage thérapeutique : Antiviraux, Oséltamivir.
- épidémiologie : Grippe humaine, Infection croisée, Manitoba.
- Chimioprévention, Facteurs temps, Flambées de maladies, Grippe humaine, Humains, Infection croisée, Modèles logistiques, Soins de longue durée, Sous-type H3N2 du virus de la grippe A, Études rétrospectives.
English descriptors
- KwdEn :
- Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Chemoprevention (methods), Cross Infection (drug therapy), Cross Infection (epidemiology), Cross Infection (microbiology), Cross Infection (prevention & control), Disease Outbreaks (prevention & control), Humans, Influenza A Virus, H3N2 Subtype, Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Logistic Models, Long-Term Care, Manitoba (epidemiology), Oseltamivir (administration & dosage), Oseltamivir (therapeutic use), Retrospective Studies, Time Factors.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Oseltamivir.
- chemical , therapeutic use : Antiviral Agents, Oseltamivir.
- geographic , epidemiology : Manitoba.
- drug therapy : Cross Infection, Influenza, Human.
- epidemiology : Cross Infection, Influenza, Human.
- methods : Chemoprevention.
- microbiology : Cross Infection.
- prevention & control : Cross Infection, Disease Outbreaks, Influenza, Human.
- Humans, Influenza A Virus, H3N2 Subtype, Logistic Models, Long-Term Care, Retrospective Studies, Time Factors.
Abstract
OBJECTIVE
This study examined the effect of the timing of administration of oseltamivir chemoprophylaxis for the control of influenza A H3N2 outbreaks among residents in long-term care facilities (LTCFs) in Manitoba, Canada, during the 2014-2015 influenza season.
METHODS
A retrospective cohort study was conducted of all LTCF influenza A H3N2 outbreaks (n=94) using a hierarchical logistic regression analysis. The main independent variable was how many days passed between the start of the outbreak and commencement of oseltamivir chemoprophylaxis. The dependent variable was whether each person in the institution developed influenza-like illness (yes or no).
RESULTS
Delay of oseltamivir chemoprophylaxis was associated with increased odds of infection in both univariate (t=5·41; df=51; P<·0001) and multivariable analyses (t=6·04; df=49; P<·0001) with an adjusted odds ratio of 1.3 (95% confidence interval [CI], 1·2-1·5) per day for influenza A H3N2.
CONCLUSIONS
The sooner chemoprophylaxis is initiated, the lower the odds of secondary infection with influenza in LTCFs during outbreaks caused by influenza A H3N2 in Manitoba. For every day that passed from the start of the outbreak to the initiation of oseltamivir, the odds of a resident at risk of infection in the facility developing symptomatic infection increased by 33%.
DOI: 10.1017/ice.2018.115
PubMed: 29893659
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of timing of oseltamivir chemoprophylaxis in controlling influenza A H3N2 outbreaks in long-term care facilities in Manitoba, Canada, 2014-2015: a retrospective cohort study.</title><author><name sortKey="Singh, Davinder" sort="Singh, Davinder" uniqKey="Singh D" first="Davinder" last="Singh">Davinder Singh</name><affiliation wicri:level="1"><nlm:affiliation>1Department of Community Health Sciences,University of Manitoba,Winnipeg,Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1Department of Community Health Sciences,University of Manitoba,Winnipeg</wicri:regionArea><wicri:noRegion>Winnipeg</wicri:noRegion></affiliation></author><author><name sortKey="Jiang, Depeng" sort="Jiang, Depeng" uniqKey="Jiang D" first="Depeng" last="Jiang">Depeng Jiang</name><affiliation wicri:level="1"><nlm:affiliation>1Department of Community Health Sciences,University of Manitoba,Winnipeg,Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1Department of Community Health Sciences,University of Manitoba,Winnipeg</wicri:regionArea><wicri:noRegion>Winnipeg</wicri:noRegion></affiliation></author><author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name><affiliation wicri:level="1"><nlm:affiliation>2Department of Medical Microbiology,Department of Pediatrics and Child Health,University of Manitoba,Winnipeg,Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>2Department of Medical Microbiology,Department of Pediatrics and Child Health,University of Manitoba,Winnipeg</wicri:regionArea><wicri:noRegion>Winnipeg</wicri:noRegion></affiliation></author><author><name sortKey="Loeppky, Carla" sort="Loeppky, Carla" uniqKey="Loeppky C" first="Carla" last="Loeppky">Carla Loeppky</name><affiliation wicri:level="1"><nlm:affiliation>1Department of Community Health Sciences,University of Manitoba,Winnipeg,Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1Department of Community Health Sciences,University of Manitoba,Winnipeg</wicri:regionArea><wicri:noRegion>Winnipeg</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29893659</idno><idno type="pmid">29893659</idno><idno type="doi">10.1017/ice.2018.115</idno><idno type="wicri:Area/Main/Corpus">000043</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000043</idno><idno type="wicri:Area/Main/Curation">000043</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000043</idno><idno type="wicri:Area/Main/Exploration">000043</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The effect of timing of oseltamivir chemoprophylaxis in controlling influenza A H3N2 outbreaks in long-term care facilities in Manitoba, Canada, 2014-2015: a retrospective cohort study.</title><author><name sortKey="Singh, Davinder" sort="Singh, Davinder" uniqKey="Singh D" first="Davinder" last="Singh">Davinder Singh</name><affiliation wicri:level="1"><nlm:affiliation>1Department of Community Health Sciences,University of Manitoba,Winnipeg,Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1Department of Community Health Sciences,University of Manitoba,Winnipeg</wicri:regionArea><wicri:noRegion>Winnipeg</wicri:noRegion></affiliation></author><author><name sortKey="Jiang, Depeng" sort="Jiang, Depeng" uniqKey="Jiang D" first="Depeng" last="Jiang">Depeng Jiang</name><affiliation wicri:level="1"><nlm:affiliation>1Department of Community Health Sciences,University of Manitoba,Winnipeg,Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1Department of Community Health Sciences,University of Manitoba,Winnipeg</wicri:regionArea><wicri:noRegion>Winnipeg</wicri:noRegion></affiliation></author><author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name><affiliation wicri:level="1"><nlm:affiliation>2Department of Medical Microbiology,Department of Pediatrics and Child Health,University of Manitoba,Winnipeg,Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>2Department of Medical Microbiology,Department of Pediatrics and Child Health,University of Manitoba,Winnipeg</wicri:regionArea><wicri:noRegion>Winnipeg</wicri:noRegion></affiliation></author><author><name sortKey="Loeppky, Carla" sort="Loeppky, Carla" uniqKey="Loeppky C" first="Carla" last="Loeppky">Carla Loeppky</name><affiliation wicri:level="1"><nlm:affiliation>1Department of Community Health Sciences,University of Manitoba,Winnipeg,Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>1Department of Community Health Sciences,University of Manitoba,Winnipeg</wicri:regionArea><wicri:noRegion>Winnipeg</wicri:noRegion></affiliation></author></analytic><series><title level="j">Infection control and hospital epidemiology</title><idno type="eISSN">1559-6834</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Chemoprevention (methods)</term><term>Cross Infection (drug therapy)</term><term>Cross Infection (epidemiology)</term><term>Cross Infection (microbiology)</term><term>Cross Infection (prevention & control)</term><term>Disease Outbreaks (prevention & control)</term><term>Humans</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Logistic Models</term><term>Long-Term Care</term><term>Manitoba (epidemiology)</term><term>Oseltamivir (administration & dosage)</term><term>Oseltamivir (therapeutic use)</term><term>Retrospective Studies</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (administration et posologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Chimioprévention ()</term><term>Facteurs temps</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Infection croisée ()</term><term>Infection croisée (microbiologie)</term><term>Infection croisée (traitement médicamenteux)</term><term>Infection croisée (épidémiologie)</term><term>Manitoba (épidémiologie)</term><term>Modèles logistiques</term><term>Oséltamivir (administration et posologie)</term><term>Oséltamivir (usage thérapeutique)</term><term>Soins de longue durée</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Manitoba</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cross Infection</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cross Infection</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemoprevention</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Infection croisée</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Cross Infection</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cross Infection</term><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Infection croisée</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>Infection croisée</term><term>Manitoba</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Influenza A Virus, H3N2 Subtype</term><term>Logistic Models</term><term>Long-Term Care</term><term>Retrospective Studies</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Chimioprévention</term><term>Facteurs temps</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Infection croisée</term><term>Modèles logistiques</term><term>Soins de longue durée</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>This study examined the effect of the timing of administration of oseltamivir chemoprophylaxis for the control of influenza A H3N2 outbreaks among residents in long-term care facilities (LTCFs) in Manitoba, Canada, during the 2014-2015 influenza season.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A retrospective cohort study was conducted of all LTCF influenza A H3N2 outbreaks (n=94) using a hierarchical logistic regression analysis. The main independent variable was how many days passed between the start of the outbreak and commencement of oseltamivir chemoprophylaxis. The dependent variable was whether each person in the institution developed influenza-like illness (yes or no).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Delay of oseltamivir chemoprophylaxis was associated with increased odds of infection in both univariate (t=5·41; df=51; P<·0001) and multivariable analyses (t=6·04; df=49; P<·0001) with an adjusted odds ratio of 1.3 (95% confidence interval [CI], 1·2-1·5) per day for influenza A H3N2.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The sooner chemoprophylaxis is initiated, the lower the odds of secondary infection with influenza in LTCFs during outbreaks caused by influenza A H3N2 in Manitoba. For every day that passed from the start of the outbreak to the initiation of oseltamivir, the odds of a resident at risk of infection in the facility developing symptomatic infection increased by 33%.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29893659</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-6834</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>08</Month></PubDate></JournalIssue><Title>Infection control and hospital epidemiology</Title><ISOAbbreviation>Infect Control Hosp Epidemiol</ISOAbbreviation></Journal><ArticleTitle>The effect of timing of oseltamivir chemoprophylaxis in controlling influenza A H3N2 outbreaks in long-term care facilities in Manitoba, Canada, 2014-2015: a retrospective cohort study.</ArticleTitle><Pagination><MedlinePgn>955-960</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/ice.2018.115</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This study examined the effect of the timing of administration of oseltamivir chemoprophylaxis for the control of influenza A H3N2 outbreaks among residents in long-term care facilities (LTCFs) in Manitoba, Canada, during the 2014-2015 influenza season.</AbstractText><AbstractText Label="METHODS">A retrospective cohort study was conducted of all LTCF influenza A H3N2 outbreaks (n=94) using a hierarchical logistic regression analysis. The main independent variable was how many days passed between the start of the outbreak and commencement of oseltamivir chemoprophylaxis. The dependent variable was whether each person in the institution developed influenza-like illness (yes or no).</AbstractText><AbstractText Label="RESULTS">Delay of oseltamivir chemoprophylaxis was associated with increased odds of infection in both univariate (t=5·41; df=51; P<·0001) and multivariable analyses (t=6·04; df=49; P<·0001) with an adjusted odds ratio of 1.3 (95% confidence interval [CI], 1·2-1·5) per day for influenza A H3N2.</AbstractText><AbstractText Label="CONCLUSIONS">The sooner chemoprophylaxis is initiated, the lower the odds of secondary infection with influenza in LTCFs during outbreaks caused by influenza A H3N2 in Manitoba. For every day that passed from the start of the outbreak to the initiation of oseltamivir, the odds of a resident at risk of infection in the facility developing symptomatic infection increased by 33%.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Davinder</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1Department of Community Health Sciences,University of Manitoba,Winnipeg,Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Depeng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1Department of Community Health Sciences,University of Manitoba,Winnipeg,Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Caeseele</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>2Department of Medical Microbiology,Department of Pediatrics and Child Health,University of Manitoba,Winnipeg,Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loeppky</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1Department of Community Health Sciences,University of Manitoba,Winnipeg,Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Infect Control Hosp Epidemiol</MedlineTA><NlmUniqueID>8804099</NlmUniqueID><ISSNLinking>0899-823X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008350" MajorTopicYN="N" Type="Geographic">Manitoba</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29893659</ArticleId><ArticleId IdType="pii">S0899823X18001150</ArticleId><ArticleId IdType="doi">10.1017/ice.2018.115</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Singh, Davinder" sort="Singh, Davinder" uniqKey="Singh D" first="Davinder" last="Singh">Davinder Singh</name></noRegion><name sortKey="Jiang, Depeng" sort="Jiang, Depeng" uniqKey="Jiang D" first="Depeng" last="Jiang">Depeng Jiang</name><name sortKey="Loeppky, Carla" sort="Loeppky, Carla" uniqKey="Loeppky C" first="Carla" last="Loeppky">Carla Loeppky</name><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000037 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000037 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29893659
|texte= The effect of timing of oseltamivir chemoprophylaxis in controlling influenza A H3N2 outbreaks in long-term care facilities in Manitoba, Canada, 2014-2015: a retrospective cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29893659" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |